Sign In
Buy RDY
$13.02
-0.0100 (-0.0767%)
At Close: Jun 03, 2026
Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript
06:09pm, Wednesday, 23'rd Jul 2025
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2026 Earnings Conference Call July 23, 2025 10:00 AM ET Company Participants Erez Israeli - CEO & Member of the Management Council Mannam Venkatanarasim
Dr. Reddy's Q1FY26 Financial Results
01:46pm, Wednesday, 23'rd Jul 2025
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #ConsolidatedFinancialResults--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2025.
India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says
10:27am, Wednesday, 23'rd Jul 2025
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wed
New Strong Sell Stocks for July 18th
06:11am, Friday, 18'th Jul 2025
ACHC, CNL and RDY have been added to the Zacks Rank #5 (Strong Sell) List on July 18, 2025.
RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar
12:31pm, Thursday, 05'th Jun 2025
Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
07:00am, Thursday, 05'th Jun 2025
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).
Dr. Reddy's Continues To Be A Good Buy At Current Valuation
11:47am, Thursday, 15'th May 2025
I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY r
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
10:20am, Monday, 12'th May 2025
Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Generics won't be affected by Trump's pricing policy, says Dr. Reddy's
03:51am, Monday, 12'th May 2025
Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that "generics normally give significant discounts," and shares how the company plans
Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript
06:03pm, Friday, 09'th May 2025
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Richa Periwal - Head, IR and Analytics Erez Israeli - CEO M V Narasimham - CF
Dr. Reddy's Q4 & Full Year FY25 Financial Results
02:53pm, Friday, 09'th May 2025
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.
RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar
10:31am, Monday, 31'st Mar 2025
Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.
GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
12:16pm, Wednesday, 19'th Mar 2025
Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #AVT03--Alvotech and Dr. Reddy's announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® an
